Complementary O O O O
and O O O O
alternative O O O O
medicine O O O O
is O O O O
commonly O O O O
used O O O O
by O O O O
patients O O O O
with O O O O
cancer. O O O O
Anywhere O O O O
from O O O O
22% O O O O
to O O O O
69% O O O O
of O O O O
cancer O O O O
patients O O O O
may O O O O
take O O O O
herbal O O O O
medicine, O O O O
medicinal O O O O
teas, O O O O
vitamins O O O O
and O O O O
minerals, O O O O
and O O O O
use O O O O
visualization O O O O
techniques. O O O O
[1](#ref-1) O O O O
There Reason 2 O O
is Reason 2 O O
often Reason 2 O O
great Reason 2 O O
pressure Reason 2 O O
put Reason 2 O O
on Reason 2 O O
oncologists Reason 2 O O
by Reason 2 O O
their Reason 2 O O
patients Reason 2 O O
to Reason 2 O O
support Reason 2 O O
the Reason 2 O O
use Reason 2 O O
of Reason 2 O O
and Reason 2 O O
even Reason 2 O O
to Reason 2 O O
prescribe Reason 2 O O
alternative Reason 2 O O
therapies Reason 2 O O
for Reason 2 O O
the Reason 2 O O
treatment Reason 2 O O
of Reason 2 O O
cancer, Reason 2 O O
in Reason 2 O O
particular Reason 2 O O
when Reason 2 O O
no Reason 2 O O
cure Reason 2 O O
or Reason 2 O O
effective Reason 2 O O
therapy Reason 2 O O
exists. Reason 2 O O
Although Reason 2 O O
oncologists Reason 2 O O
might Reason 2 O O
dissuade Reason 2 O O
their Reason 2 O O
patients Reason 2 O O
from Reason 2 O O
pursuing Reason 2 O O
therapies Reason 2 O O
that Reason 2 O O
are Reason 2 O O
likely Reason 2 O O
to Reason 2 O O
be Reason 2 O O
ineffective, Reason 2 O O
in Reason 2 O O
the Reason 2 O O
face Reason 2 O O
of Reason 2 O O
desperate Reason 2 O O
circumstances Reason 2 O O
many Reason 2 O O
patients Reason 2 O O
insist Reason 2 O O
on Reason 2 O O
taking Reason 2 O O
complementary Reason 2 O O
and Reason 2 O O
alternative Reason 2 O O
medicine Reason 2 O O
concurrently Reason 2 O O
with Reason 2 O O
standard" Reason 2 O O
therapies. Reason 2 O O
A O O O O
critical O O O O
concern O O O O
of O O O O
most O O O O
oncologists O O O O
is O O O O
whether O O O O
use O O O O
of O O O O
complementary O O O O
and O O O O
alternative O O O O
therapies O O O O
can O O O O
cause O O O O
harm, O O O O
especially O O O O
when O O O O
taken O O O O
concurrently O O O O
with O O O O
a O O O O
chemotherapy O O O O
regimen O O O O
that O O O O
has O O O O
a O O O O
narrow O O O O
therapeutic O O O O
index. O O O O
But O O O O
should O O O O
our O O O O
concern O O O O
move O O O O
beyond O O O O
adverse O O O O
events? O O O O
If O O O O
a O O O O
large O O O O
proportion O O O O
of O O O O
patients O O O O
are O O O O
interested O O O O
in O O O O
alternative O O O O
remedies O O O O
that O O O O
have O O O O
biologically O O O O
plausible O O O O
therapeutic O O O O
potential, O O O O
it Reason 5 O O
is Reason 5 O O
the Reason 5 O O
responsibility Reason 5 O O
of Reason 5 O O
conventional Reason 5 O O
medicine Reason 5 O O
to Reason 5 O O
encourage Reason 5 O O
the Reason 5 O O
preclinical Reason 5 O O
and Reason 5 O O
clinical Reason 5 O O
research Reason 5 O O
necessary Reason 5 O O
to Reason 5 O O
demonstrate Reason 5 O O
or Reason 5 O O
refute Reason 5 O O
the Reason 5 O O
efficacy Reason 5 O O
and Reason 5 O O
safety Reason 5 O O
of Reason 5 O O
these Reason 5 O O
treatments, Reason 5 O O
according Reason 5 O O
to Reason 5 O O
the Reason 5 O O
scientific Reason 5 O O
method Reason 5 O O
and Reason 5 O O
rigorous Reason 5 O O
standards Reason 5 O O
set Reason 5 O O
for Reason 5 O O
conventional Reason 5 O O
cancer Reason 5 O O
therapies. Reason 5 O O
[2](#ref-2) O O O O
The O O O O
Office O O O O
of O O O O
Cancer O O O O
Complementary O O O O
and O O O O
Alternative O O O O
Medicine O O O O
(OCCAM) O O O O
at O O O O
the O O O O
US O O O O
National O O O O
Cancer O O O O
Institute O O O O
was O O O O
established O O O O
in O O O O
1998 O O O O
for O O O O
this O O O O
purpose. O O O O
Not O O O O
only O O O O
does O O O O
it O O O O
warn O O O O
people O O O O
of O O O O
the O O O O
harmful O O O O
effects O O O O
of O O O O
some O O O O
alternative O O O O
therapies, O O O O
it O O O O
also O O O O
directs O O O O
them O O O O
toward O O O O
available O O O O
clinical O O O O
trials O O O O
of O O O O
complementary O O O O
and O O O O
alternative O O O O
therapies O O O O
for O O O O
cancer O O O O
and O O O O
provides O O O O
peer O O O O
review O O O O
and O O O O
funding O O O O
for O O O O
research O O O O
into O O O O
these O O O O
therapies O O O O
( O O O O
[www.cancer.gov/cam/](http://www.cancer.gov/cam/)). O O O O
OCCAM O O O O
also O O O O
provides O O O O
guidelines O O O O
to O O O O
standardize O O O O
the O O O O
reporting O O O O
of O O O O
cases O O O O
of O O O O
effective O O O O
therapies. O O O O
This O O O O
format O O O O
was O O O O
used O O O O
by O O O O
Padayatty O O O O
and O O O O
associates O O O O
in O O O O
this O O O O
issue O O O O
(page O O O O
937) O O O O
to O O O O
report O O O O
on O O O O
3 O O O O
cases O O O O
where O O O O
advanced Reason 2 O O
malignant Reason 2 O O
disease Reason 2 O O
was Reason 2 O O
effectively Reason 2 O O
treated Reason 2 O O
with Reason 2 O O
high Reason 2 O O
doses Reason 2 O O
of Reason 2 O O
intravenous Reason 2 O O
vitamin Reason 2 O O
C Reason 2 O O
therapy. Reason 2 O O
[3](#ref-3) O O O O
